Understanding how a specific gene affects a type of nerve sheath tumor in patients with neurofibromatosis type 1.
Official title: Regulation of MPNST pathogenesis by Chromosome 8 gene, UBR5
Funded at Washington University · NIH-11012336 · Data updated 2026-11-12
This study is looking at how a gene called UBR5 affects the growth of a type of cancer called malignant peripheral nerve sheath tumors in people with neurofibromatosis type 1, with the hope of finding new treatments to help those battling this tough disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | January 18, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $451,578 |
| NIH project number | 5R01NS134815-02 |
| Project ID | NIH-11012336 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with neurofibromatosis type 1 who are at risk of developing malignant peripheral nerve sheath tumors.
✕Less likely to help
Patients without neurofibromatosis type 1 or those who do not have MPNST may not benefit from this research.
What this research studies
This research investigates the role of the UBR5 gene in the development of malignant peripheral nerve sheath tumors (MPNST) in patients with neurofibromatosis type 1 (NF1). By using patient-derived xenografts, the study aims to understand how changes in chromosome 8 contribute to tumor growth and survival. The researchers will explore when these genetic changes occur during tumor progression and how targeting UBR5 could lead to new treatment options. This approach may help identify more effective therapies for patients suffering from this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve survival rates for patients with MPNST.
How similar studies have gone: Previous research has shown promising results in targeting genetic abnormalities in cancer, suggesting that this approach could be effective.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Hirbe, Angela Christine — Washington University
- Study coordinator: Hirbe, Angela Christine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.